Transforming growth factor‑β, insulin‑like growth factor I/insulin‑like growth factor I receptor and vascular endothelial growth factor‑A: Prognostic and predictive markers in triple‑negative and non‑triple‑negative breast cancer

Bahhnassy,Abeer; Mohanad,Marwa; Shaarawy,Sabry; Ismail,Manal F.; El‑Bastawisy,Ahmed; Ashmawy,Abeer M.; Zekri,Abdel‑Rahman

doi:10.3892/mmr.2015.3560

Transforming growth factor‑β, insulin‑like growth factor I/insulin‑like growth factor I receptor and vascular endothelial growth factor‑A: Prognostic and predictive markers in triple‑negative and non‑triple‑negative breast cancer

Authors:
- Abeer Bahhnassy
- Marwa Mohanad
- Sabry Shaarawy
- Manal F. Ismail
- Ahmed El‑Bastawisy
- Abeer M. Ashmawy
- Abdel‑Rahman Zekri
View Affiliations

Affiliations: Molecular Pathology Unit, Pathology Department, National Cancer Institute, Cairo University, Cairo 11796, Egypt, Department of Biochemistry, Faculty of Pharmacy, Misr University for Science and Technology, Cairo 11796, Egypt, Department of Cancer Biology, National Cancer Institute, Cairo University, Cairo 11796, Egypt, Faculty of Pharmacy, Cairo University, Cairo 11796, Egypt, Department of Medical Oncology, National Cancer Institute, Cairo University, Cairo 11796, Egypt
Published online on: March 27, 2015 https://doi.org/10.3892/mmr.2015.3560
Pages: 851-864
Copyright: © Bahhnassy et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the current study, the prognostic and predictive values of serum transforming growth factor‑β1 (TGF‑β1), insulin‑like growth factor I (IGF‑I)/IGF‑I receptor (IGF‑IR) and vascular endothelial growth factor‑A (VEGF‑A) were evaluated in triple‑negative and non‑triple‑negative breast cancer (TNBC and non‑TNBC). The aim was to identify a group of serological biomarkers and to identify possible candidates for targeted therapy in patients with TNBC and non‑TNBC. Protein levels of TGF‑β1, IGF‑I/IGF‑IR and VEGF‑A in the serum were measured in 43 TNBC, 53 non‑TNBC and 20 normal control participants using quantitative ELISA assays. Results were correlated against standard prognostic factors, response to treatment and survival. TNBC was identified to be associated with poor prognosis and serum levels of VEGF‑A and IGF/IGF‑IR were significantly higher in the TNBC group compared with the non‑TNBC group. IGF‑IR and VEGF‑A overexpression was observed to be correlated with TGF‑β1 expression and all of the markers investigated were associated with metastasis and disease progression. In the multivariate analysis, VEGF‑A, IGF‑I and IGF‑IR were observed to be independent predictors for overall survival, whereas TGF‑β1 and lymph node status were identified as independent predictors for disease‑free survival. The overall response rate was significantly lower in patients with TNBC and those with high levels of TGF‑β1, IGF‑I/IGF‑IR and VEGF‑A. In view of the present results, it was concluded that TGF‑β1, IGF‑I/IGF‑IR and VEGF‑A overexpression is associated with the presence of aggressive tumors, which exhibit an increased probability of metastasis, a poor response to treatment and reduced survival rate. This indicates that VEGF‑A, IGF‑IR and IGF‑I have the potential to be used as surrogate biomarkers and are promising candidates for targeted therapy, particularly in patients with TNBC.

View Figures

View References

1	Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
2	Litzenburger BC, Creighton CJ, Tsimelzon A, et al: High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. Clin Cancer Res. 17:2314–2327. 2011. View Article : Google Scholar :
3	Rakha EA, Reis-Filho JS and Ellis IO: Basal-like breast cancer: a critical review. J Clin Oncol. 26:2568–2581. 2008. View Article : Google Scholar : PubMed/NCBI
4	Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
5	Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, et al: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 26:1275–1281. 2008. View Article : Google Scholar : PubMed/NCBI
6	Brouckaert O, Wildiers H, Floris G and Neven P: Update on triple-negative breast cancer: prognosis and management strategies. Int J Womens Health. 4:511–520. 2012.PubMed/NCBI
7	Cao H, Yan M, Wang S, Zheng T, Xu R, Chen Y and Liu Y: Clinical characteristics and prognosis of triple-negative breast cancer. Chin-Ger J Clin Oncol. 8:471–475. 2009. View Article : Google Scholar
8	Oakman C, Moretti E, Galardi F, Biagioni C, Santarpia L, Biganzoli L and Di Leo A: Adjuvant systemic treatment for individual patients with triple negative breast cancer. Breast. 20(Suppl 3): S135–S141. 2011. View Article : Google Scholar : PubMed/NCBI
9	Kashiwagi S, Yashiro M, Takashima T, Nomura S, Noda S, Kawajiri H, Ishikawa T, Wakasa K and Hirakawa K: Significance of E-cadherin expression in triple-negative breast cancer. Br J Cancer. 103:249–255. 2010. View Article : Google Scholar : PubMed/NCBI
10	Dumont N, Bakin AV and Arteaga CL: Autocrine transforming growth factor-beta signaling mediates Smad-independent motility in human cancer cells. J Biol Chem. 278:3275–3285. 2003. View Article : Google Scholar
11	Tan AR, Alexe G and Reiss M: Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer? Breast Cancer Res Treat. 115:453–495. 2009. View Article : Google Scholar :
12	Adams J, Carder PJ, Downey S, Forbes MA, MacLennan K, Allgar V, Kaufman S, Hallam S, Bicknell R, Walker JJ, et al: Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res. 60:2898–2905. 2000.PubMed/NCBI
13	George ML, Eccles SA, Tutton MG, Abulafi AM and Swift RI: Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? Clin Cancer Res. 6:3147–3152. 2000.PubMed/NCBI
14	Pollak MN, Schernhammer ES and Hankinson SE: Insulin-like growth factors and neoplasia. Nat Rev Cancer. 4:505–518. 2004. View Article : Google Scholar : PubMed/NCBI
15	Hankinson SE: Circulating levels of sex steroids and prolactin in premenopausal women and risk of breast cancer. Adv Exp Med Biol. 617:161–169. 2008.PubMed/NCBI
16	Reiss K, Wang JY, Romano G, Furnari FB, Cavenee WK, Morrione A, Tu X and Baserga R: IGF-I receptor signaling in a prostatic cancer cell line with a PTEN mutation. Oncogene. 19:2687–2694. 2000. View Article : Google Scholar : PubMed/NCBI
17	Valentinis B, Navarro M, Zanocco-Marani T, Edmonds P, McCormick J, Morrione A, Sacchi A, Romano G, Reiss K and Baserga R: Insulin receptor substrate-1, p70S6K, and cell size in transformation and differentiation of hemopoietic cells. J Biol Chem. 275:25451–25459. 2000. View Article : Google Scholar : PubMed/NCBI
18	Guerra FK, Eijan AM, Puricelli L, Alonso DF, Bal de Kier Joffé E, Kornblihgtt AR, Charreau EH and Elizalde PV: Varying patterns of expression of insulin-like growth factors I and II and their receptors in murine mammary adenocarcinomas of different metastasizing ability. Int J Cancer. 65:812–820. 1996. View Article : Google Scholar : PubMed/NCBI
19	Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
20	Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
21	Iva nović V, To dorović-Ra ković N, D emajo M, Nesković-Konstantinović Z, Subota V, Ivanisević-Milovanović O and Nikolić-Vukosavljević D: Elevated plasma levels of transforming growth factor-beta 1 (TGF-beta 1) in patients with advanced breast cancer: association with disease progression. Eur J Cancer. 39:454–461. 2003. View Article : Google Scholar
22	Jones C, Nonni AV, Fulford L, Merrett S, Chaggar R, Eusebi V and Lakhani SR: CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation. Br J Cancer. 85:422–427. 2001. View Article : Google Scholar : PubMed/NCBI
23	Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 100:8418–8423. 2003. View Article : Google Scholar : PubMed/NCBI
24	Wang X, Chao L, Ma G, Chen L, Tian B, Zang Y and Sun J: Increased expression of osteopontin in patients with triple-negative breast cancer. Eur J Clin Invest. 38:438–446. 2008. View Article : Google Scholar : PubMed/NCBI
25	Sheen-Chen SM, Chen HS, Sheen CW, Eng HL and Chen WJ: Serum levels of transforming growth factor beta1 in patients with breast cancer. Arch Surg. 136:937–940. 2001. View Article : Google Scholar : PubMed/NCBI
26	Massagué J, Cheifetz S, Laiho M, Ralph DA, Weis FM and Zentella A: Transforming growth factor-beta. Cancer Surv. 12:81–103. 1992.PubMed/NCBI
27	Reiss M: TGF-beta and cancer. Microbes Infect. 1:1327–1347. 1999. View Article : Google Scholar : PubMed/NCBI
28	Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, et al: Molecular definition of breast tumor heterogeneity. Cancer Cell. 11:259–273. 2007. View Article : Google Scholar : PubMed/NCBI
29	Buck M, von der Fecht J and Knabbe C: Antiestrogenic regulation of transforming growth factor beta receptors I and II in human breast cancer cells. Ann NY Acad Sci. 963:140–143. 2002. View Article : Google Scholar : PubMed/NCBI
30	Kang Y, He W, Tulley S, Gupta GP, Serganova I, Chen CR, Manova-Todorova K, Blasberg R, Gerald WL and Massagué J: Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci USA. 102:13909–13914. 2005. View Article : Google Scholar : PubMed/NCBI
31	Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, Massagué J, Mundy GR and Guise TA: TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest. 103:197–206. 1999. View Article : Google Scholar : PubMed/NCBI
32	Tang B, Vu M, Booker T, Santner SJ, Miller FR, Anver MR and Wakefield LM: TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest. 112:1116–1124. 2003. View Article : Google Scholar : PubMed/NCBI
33	Kingsley LA, Fournier PG, Chirgwin JM and Guise TA: Molecular biology of bone metastasis. Mol Cancer Ther. 6:2609–2617. 2007. View Article : Google Scholar : PubMed/NCBI
34	Kareddula A, Zachariah E, Notterman D and Reiss M: Transforming growth factor-b signaling strength determines target gene expression profile in human keratinocytes. J Epithel Biol Pharmaco. 1:40–94. 2008. View Article : Google Scholar
35	Marrogi AJ, Munshi A, Merogi AJ, Ohadike Y, El-Habashi A, Marrogi OL and Freeman SM: Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma. Int J Cancer. 74:492–501. 1997. View Article : Google Scholar : PubMed/NCBI
36	Gorsch SM, Memoli VA, Stukel TA, Gold LI and Arrick BA: Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res. 52:6949–6952. 1992.PubMed/NCBI
37	Desruisseau S, Palmari J, Giusti C, Romain S, Martin PM and Berthois Y: Determination of TGFbeta1 protein level in human primary breast cancers and its relationship with survival. Br J Cancer. 94:239–246. 2006. View Article : Google Scholar : PubMed/NCBI
38	Dave H, Shah M, Trivedi S and Shukla S: Prognostic utility of circulating transforming growth factor beta 1 in breast cancer patients. Int J Biol Markers. 27:53–59. 2012. View Article : Google Scholar
39	Taha FM, Zeeneldin AA, Helal AM, Gaber AA, Sallam YA, Ramadan H and Moneer MM: Prognostic value of serum vascular endothelial growth factor in Egyptian females with metastatic triple negative breast cancer. Clin Biochem. 42:1420–1426. 2009. View Article : Google Scholar : PubMed/NCBI
40	Berns EM, Klijn JG, Look MP, et al: Combined vascular endo-thelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer. Clin Cancer Res. 9:1253–1258. 2003.PubMed/NCBI
41	Foekens JA, Peters HA, Grebenchtchikov N, Look MP, Meijer-van Gelder ME, Geurts-Moespot A, van der Kwast TH, Sweep CG and Klijn JG: High tumor levels of vascular endo-thelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res. 61:5407–5414. 2001.PubMed/NCBI
42	Greenberg S and Rugo HS: Triple-negative breast cancer: role of antiangiogenic agents. Cancer J. 16:33–38. 2010. View Article : Google Scholar : PubMed/NCBI
43	Björndahl M, Cao R, Nissen LJ, et al: Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo. Proc Natl Acad Sci USA. 102:15593–15598. 2005. View Article : Google Scholar : PubMed/NCBI
44	Moschos SJ and Mantzoros CS: The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology. 63:317–332. 2002. View Article : Google Scholar : PubMed/NCBI
45	Rubin R and Baserga R: Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity. Lab Invest. 73:311–331. 1995.PubMed/NCBI
46	Dunn SE, Kari FW, French J, Leininger JR, Travlos G, Wilson R and Barrett JC: Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res. 57:4667–4672. 1997.PubMed/NCBI
47	Gooch JL, Van Den Berg CL and Yee D: Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death - proliferative and anti-apoptotic effects. Breast Cancer Res Treat. 56:1–10. 1999. View Article : Google Scholar : PubMed/NCBI
48	Decensi A, Veronesi U, Miceli R, Johansson H, Mariani L, Camerini T, Di Mauro MG, Cavadini E, De Palo G, Costa A, et al: Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide. Clin Cancer Res. 9:4722–4729. 2003.PubMed/NCBI
49	Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K and Vogel V: Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst. 91:1829–1846. 1999. View Article : Google Scholar : PubMed/NCBI
50	Yarden RI, Wilson MA and Chrysogelos SA: Estrogen suppression of EGFR expression in breast cancer cells: a possible mechanism to modulate growth. J Cell Biochem. 81(Suppl 36): 232–246. 2001. View Article : Google Scholar
51	Haffner MC, Petridou B, Peyrat JP, Révillion F, Müller-Holzner E, Daxenbichler G, Marth C and Doppler W: Favorable prognostic value of SOCS2 and IGF-I in breast cancer. BMC Cancer. 7:1362007. View Article : Google Scholar : PubMed/NCBI
52	Shin A, Ren Z, Shu XO, Cai Q, Gao YT and Zheng W: Expression patterns of insulin-like growth factor 1 (IGF-I) and its receptor in mammary tissues and their associations with breast cancer survival. Breast Cancer Res Treat. 105:55–61. 2007. View Article : Google Scholar
53	Minami CA, Chung DU and Chang HR: Management options in triple-negative breast cancer. Breast Cancer (Auckl). 5:175–199. 2011.
54	Sarfstein R, Maor S, Reizner N, Abramovitch S and Werner H: Transcriptional regulation of the insulin-like growth factor-I receptor gene in breast cancer. Mol Cell Endocrinol. 252:241–246. 2006. View Article : Google Scholar : PubMed/NCBI
55	Valentinis B, Romano G, Peruzzi F, Morrione A, Prisco M, Soddu S, Cristofanelli B, Sacchi A and Baserga R: Growth and differentiation signals by the insulin-like growth factor 1 receptor in hemopoietic cells are mediated through different pathways. J Biol Chem. 274:12423–12430. 1999. View Article : Google Scholar : PubMed/NCBI
56	Munagala R, Aqil F and Gupta RC: Promising molecular targeted therapies in breast cancer. Indian J Pharmacol. 43:236–245. 2011. View Article : Google Scholar : PubMed/NCBI
57	Shimizu C, Hasegawa T, Tani Y, Takahashi F, Takeuchi M, Watanabe T, Ando M, Katsumata N and Fujiwara Y: Expression of insulin-like growth factor 1 receptor in primary breast cancer: immunohistochemical analysis. Hum Pathol. 35:1537–1542. 2004. View Article : Google Scholar : PubMed/NCBI
58	Pizon M, Zimon DS, Pachmann U and Pachmann K: Insulin-like growth factor receptor I (IGF-IR) and vascular endothelial growth factor receptor 2 (VEGFR-2) are expressed on the circulating epithelial tumor cells of breast cancer patients. PLoS One. 8:e568362013. View Article : Google Scholar : PubMed/NCBI
59	Grau AM, Wen W, Ramroopsingh DS, Gao YT, Zi J, Cai Q, Shu XO and Zheng W: Circulating transforming growth factor-beta-1 and breast cancer prognosis: results from the Shanghai Breast Cancer Study. Breast Cancer Res Treat. 112:335–341. 2008. View Article : Google Scholar